XG2002
/ Xgene Pharma, RaQualia
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 30, 2024
A Phase I, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of XG2002 Oral Administration in Healthy Adult Volunteers
(ANZCTR)
- P1 | N=32 | Recruiting | Sponsor: Xgene Pharmaceutical Pty Ltd | Not yet recruiting ➔ Recruiting | N=48 ➔ 32 | Initiation date: Apr 2024
Enrollment change • Enrollment open • Trial initiation date • Pain
1 to 1
Of
1
Go to page
1